Introduction As mentioned in Chapter 1, people with Down syndrome (DS) develop Alzheimer’s disease (AD) neuropathology by 40 years of age (Chapter 2), and in most, dementia develops in their…
Acknowledgments This work was supported by National Institutes of Health grants: P01 HD035897, U54 HD079123, U01 AG051412, and R01 AG014673 as well as funds from the New York State Office…
Alzheimer’s disease in adults with Down syndrome As described in Chapter 1, Down syndrome (DS) is one of the most common genetic diseases. Adults with DS carry three copies of…
Epidemiology While the prevalence rates of physical health conditions, and in particular Alzheimer’s disease (AD), in people with Down syndrome (DS) have been extensively researched [1, 2] (also see Chapters…
Chapter 13: Contributions of the neurological examination to the diagnosis of dementia in Down syndrome Ira T. Lotta,*; H. Diana Rosasb,,c; Florence Laib; Shahid Zamand a Department of Pediatrics, School of…
Proteomic and metabolomic methodologies In the general AD population, proteomic and metabolomic studies are under close scrutiny as inconsistency in outcomes and variability in preanalytic methods (sample collection, processing, storage,…
Prevalence The prevalence of Down syndrome (DS) in the United States is believed to be about 8.27 per 10,000 persons. Based upon birth prevalence and death certificate data the US…
Chapter 12 Assessment and management of substance abuse comorbidity in people with schizophrenia KEY POINTS • Substance abuse and dependence are common amongst people with schizophrenia. • Assessment requires a…
Chapter 10 Depression and schizophrenia KEY POINTS • Comorbid depression is frequent, particularly in early stages of schizophrenia. • Comorbid depression is a poor prognostic indicator for functional recovery, quality…
Chapter 3 Why are psychiatric comorbidities so common in schizophrenia and why are they so often missed in clinical practice? KEY POINTS • The comorbidity of schizophrenia with other psychiatric…
